Top-Rated StocksTop-RatedNASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free IOVA Stock Alerts $11.16 -0.56 (-4.78%) (As of 02:22 PM ET) Add Compare Share Share Today's Range$11.05▼$11.6950-Day Range$9.15▼$17.4752-Week Range$3.21▼$18.33Volume3.20 million shsAverage Volume8.74 million shsMarket Capitalization$3.12 billionP/E RatioN/ADividend YieldN/APrice Target$24.64 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Iovance Biotherapeutics alerts: Email Address Iovance Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside117.1% Upside$24.64 Price TargetShort InterestBearish21.08% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment-0.07Based on 9 Articles This WeekInsider TradingAcquiring Shares$2.29 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.40) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.56 out of 5 starsMedical Sector69th out of 918 stocksBiological Products, Except Diagnostic Industry8th out of 152 stocks 4.5 Analyst's Opinion Consensus RatingIovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIovance Biotherapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted21.08% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Iovance Biotherapeutics has recently decreased by 2.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIovance Biotherapeutics has received a 70.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Iovance Biotherapeutics is -0.82. Previous Next 1.1 News and Social Media Coverage News SentimentIovance Biotherapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Iovance Biotherapeutics this week, compared to 6 articles on an average week.Search InterestOnly 95 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 44 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,287,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.40) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -6.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -6.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 4.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHere’s how to start a “Weekend Side Hustle” from your sofaHere’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.Weekend after weekend! About Iovance Biotherapeutics Stock (NASDAQ:IOVA)Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Read More IOVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOVA Stock News HeadlinesApril 9, 2024 | marketbeat.comThe Top 5 Analysts Ranked by Marketbeat and Stocks They CoverMarketbeat's many investor tools include analysts' rankings and sentiment trackers. These tools help investors and traders gauge market sentiment, showing trends and changes, updated revisions, and new reports.April 9, 2024 | marketbeat.comThe Top 5 Analysts Ranked by Marketbeat and Stocks They Cover (IOVA)Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI.April 19, 2024 | The Bull Report (Ad)Healthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.April 18, 2024 | americanbankingnews.comZacks Research Comments on Iovance Biotherapeutics, Inc.'s FY2024 Earnings (NASDAQ:IOVA)April 17, 2024 | fool.comIs Iovance Biotherapeutics Stock a Buy Now?April 17, 2024 | nasdaq.comIovance Biotherapeutics Enters Oversold Territory (IOVA)April 17, 2024 | nasdaq.comFirst Week of May 31st Options Trading For Iovance Biotherapeutics (IOVA)April 17, 2024 | finance.yahoo.comMarket Sentiment Around Loss-Making Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)April 19, 2024 | The Bull Report (Ad)Healthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.April 9, 2024 | seekingalpha.comIovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent ResultsApril 5, 2024 | fool.comBetter Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR TherapeuticsApril 3, 2024 | bizjournals.comObsidian lands $160M Series C —but IPO still in the cardsApril 3, 2024 | markets.businessinsider.comBuy Rating for Werewolf Therapeutics: Innovation and Financial Stability Signal Promising Future in ImmunotherapyApril 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)March 29, 2024 | msn.comCity Council wants the gene therapy industry to hire Philadelphians without a college degreeMarch 29, 2024 | finance.yahoo.comIovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?March 26, 2024 | fool.com2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall StreetMarch 26, 2024 | seekingalpha.comIovance Biotherapeutics: Initial Amtagvi Launch In FocusMarch 22, 2024 | globenewswire.comIovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)March 19, 2024 | finance.yahoo.comIovance Biotherapeutics (NASDAQ:IOVA) shareholders are still up 122% over 1 year despite pulling back 7.1% in the past weekMarch 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Silk Road Medical (SILK), Arcellx Inc (ACLX)March 14, 2024 | markets.businessinsider.comPiper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To KnowMarch 7, 2024 | markets.businessinsider.comTruist Securities Maintains Buy Rating for Iovance Biotherapeutics: Here's What You Need To KnowMarch 7, 2024 | fool.com1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?March 6, 2024 | markets.businessinsider.comPositive Outlook for Iovance Biotherapeutics: Buy Rating Justified by Clinical Advancements and Strong FinancialsMarch 6, 2024 | fool.comIovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street AnalystSee More Headlines Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/19/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IOVA CUSIPN/A CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees557Year Founded2013Price Target and Rating Average Stock Price Target$24.64 High Stock Price Target$34.00 Low Stock Price Target$17.00 Potential Upside/Downside+110.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-444,040,000.00 Net MarginsN/A Pretax Margin-37,638.01% Return on Equity-70.93% Return on Assets-55.25% Debt Debt-to-Equity RatioN/A Current Ratio2.79 Quick Ratio2.70 Sales & Book Value Annual Sales$1.19 million Price / Sales2,750.85 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book5.14Miscellaneous Outstanding Shares279,310,000Free Float250,259,000Market Cap$3.27 billion OptionableOptionable Beta0.62 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Frederick G. Vogt Esq. (Age 50)J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary Comp: $1.39MMr. Jean-Marc Bellemin M.B.A. (Age 51)CFO, Principal Accounting Officer & Treasurer Comp: $932.2kDr. Igor P. Bilinsky (Age 51)Chief Operating Officer Comp: $932.2kDr. Friedrich Graf Finckenstein M.D. (Age 57)Chief Medical Officer Comp: $1.06MMs. Sara PellegrinoVice President of Investor Relations & Public RelationsMs. Tracy WintonSenior Vice President of Human ResourcesMr. Howard B. Johnson M.B.A. (Age 64)Chief Business Officer Mr. James Ziegler M.B.A.Executive Vice President of CommercialDr. Raj K. Puri M.D.Ph.D., Executive VP of Regulatory Strategy & Translational MedicineMr. Brian Shew M.B.A.Senior VP & Head of Digital and Information TechnologyMore ExecutivesKey CompetitorsImmunityBioNASDAQ:IBRXSpringWorks TherapeuticsNASDAQ:SWTXApogee TherapeuticsNASDAQ:APGEArcellxNASDAQ:ACLXImmunocoreNASDAQ:IMCRView All CompetitorsInsiders & InstitutionsDiversified Trust CoBought 1,999 shares on 4/18/2024Ownership: 0.006%Hennion & Walsh Asset Management Inc.Bought 121,395 shares on 4/17/2024Ownership: 0.146%Grimes & Company Inc.Sold 5,748 shares on 4/17/2024Ownership: 0.010%Vanguard Group Inc.Bought 669,350 shares on 3/11/2024Ownership: 8.168%Wellington Management Group LLPBought 53,572 shares on 3/5/2024Ownership: 0.056%View All Insider TransactionsView All Institutional Transactions IOVA Stock Analysis - Frequently Asked Questions Should I buy or sell Iovance Biotherapeutics stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOVA shares. View IOVA analyst ratings or view top-rated stocks. What is Iovance Biotherapeutics' stock price target for 2024? 10 analysts have issued twelve-month price objectives for Iovance Biotherapeutics' shares. Their IOVA share price targets range from $17.00 to $34.00. On average, they predict the company's stock price to reach $24.64 in the next twelve months. This suggests a possible upside of 117.1% from the stock's current price. View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts. How have IOVA shares performed in 2024? Iovance Biotherapeutics' stock was trading at $8.13 at the beginning of the year. Since then, IOVA stock has increased by 39.6% and is now trading at $11.35. View the best growth stocks for 2024 here. When is Iovance Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our IOVA earnings forecast. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.01. The biotechnology company earned $0.48 million during the quarter, compared to analysts' expectations of $1.44 million. During the same quarter last year, the firm posted ($0.64) earnings per share. What ETFs hold Iovance Biotherapeutics' stock? ETFs with the largest weight of Iovance Biotherapeutics (NASDAQ:IOVA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Harbor Disruptive Innovation ETF (INNO). What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), Xtrackers California Municipal Bond ETF (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX). Who are Iovance Biotherapeutics' major shareholders? Iovance Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.15%), Grimes & Company Inc. (0.01%) and Diversified Trust Co (0.01%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IOVA) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIThe #1 Crypto for 2024InvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits1970’s computer coder issues shocking A.I. warningTradeSmithSHOCKING Crypto Leak…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.